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Elevated serum CXCL16 is an independent
predictor of poor survival in ovarian cancer
and may reflect pro-metastatic ADAM
protease activity
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Background: In certain cancers, expression of CXCL16 and its receptor CXCR6 associate with lymphocyte infiltration,
possibly aiding anti-tumour immune response. In other cancers, CXCL16 and CXCR6 associate with pro-metastatic
activity. In the current study, we aimed to characterise the role of CXCL16, sCXCL16, and CXCR6 in ovarian
cancer (OC).
Methods: CXCL16/CXCR6 expression was analysed on tissue microarray containing 306 OC patient samples. Pre-treatment serum
sCXCL16 was determined in 118 patients using ELISA. In vitro, (primary) OC cells were treated with an ADAM-10/ADAM-17
inhibitor (TAPI-2) and an ADAM-10-specific inhibitor (GI254023x), whereupon CXCL16 levels were evaluated on the cell membrane
(immunofluorescent analysis, western blots) and in culture supernatants (ELISA). In addition, cell migration was assessed using
scratch assays.
Results: sCXCL16 independently predicted for poor survival (hazard ratio¼ 2.28, 95% confidence interval¼ 1.29–4.02, P¼ 0.005),
whereas neither CXCL16 nor CXCR6 expression correlated with survival. Further, CXCL16/CXCR6 expression and serum sCXCL16
levels did not associate with lymphocyte infiltration. In vitro inhibition of both ADAM-17 and ADAM-10, but especially the latter,
decreased CXCL16 membrane shedding and strongly reduced cell migration of A2780 and cultured primary OC-derived
malignant cells.
Conclusions: High serum sCXCL16 is a prognostic marker for poor survival of OC patients, possibly reflecting ADAM-10 and
ADAM-17 pro-metastatic activity. Therefore, serum sCXCL16 levels may be a pseudomarker that identifies patients with highly
metastatic tumours.
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Epithelial ovarian cancer (OC) is the most lethal gynaecologic
cancer (Jemal et al, 2009). Chances of survival are highly
dependent on a timely diagnosis before the cancer has spread
beyond the ovaries. However, because of the relatively asympto-
matic nature of early-stage OC, the disease usually is not
recognised for an extended period of time (Vine et al, 2003).
Hence, 70% of OC cases are detected in a late and metastatic
disease stage, by which time survival rates have dropped to only
10%–30% (Hennessy et al, 2009). Metastasis is a multifactorial
process with recent evidence emerging on the importance of
chemokines and chemokine receptor interactions (Kruizinga et al,
2009; Barbieri et al, 2010).
Chemokines are a family of structurally similar proteins that are
classified into four subfamilies, that is, the CXC, CC, C, and CX3C
subfamily, based on the configuration of their N-terminal cysteine
residues (Zlotnik and Yoshie, 2000). Among these, the chemokine
CXCL16 and its cognate chemokine receptor CXCR6 is of
particular interest. CXCL16 is normally expressed on macrophages,
dendritic cells, monocytes, and B cells and serves as an adhesion
molecule for neighbouring cells expressing CXCR6. In addition,
CXCL16 is a scavenger receptor for oxidised low-density
lipoproteins and phosphatidyl serines (Deng et al, 2010). CXCL16
has been found to be cleaved by metalloproteinases of the ADAM
family, yielding a soluble form (sCXCL16; Abel et al, 2004; Gough
et al, 2004; Schramme et al, 2008). This sCXCL16 has been
detected in the serum of various types of cancer patients.
The physiological role of the CXCL16/CXCR6 axis in cancer is
unclear, with pro-metastatic as well as anti-tumorigenic functions
being reported. In prostate cancer, high expression of CXCL16 and
CXCR6 as well as high serum sCXCL16 levels were associated with
a more aggressive tumour phenotype (Lu et al, 2008; Wang et al,
2008; Darash-Yahana et al, 2009) and increased formation of
metastases (Hu et al, 2008; Sung et al, 2008; Ha et al, 2011).
Similarly, high serum levels of sCXCL16 in colorectal cancer
patients were associated with recurrent liver metastasis and poor
prognosis (Matsushita et al, 2012). In contrast, in a murine model
of colorectal cancer the expression of CXCL16 inhibited formation
of liver metastases by recruitment of CXCR6þ T cells and NK cells
(Kee et al, 2013). The latter data corroborate with the finding that
CXCL16 expression in colorectal cancer patients associated with an
increased number of CD4þ and CD8þ tumour infiltrating
lymphocytes and a better prognosis (Hojo et al, 2007). For OC, a
microarray-based study reported that CXCR6 gene expression
associated with tumour infiltration of CD8þ T cells and thus with
better survival (Callahan et al, 2008). In contrast, high CXCL16
expression was associated with poor survival in a univariate
analysis in an immunohistochemical study in 56 OC patients (Guo
et al, 2011). Thus, the CXCL16/CXCR6 axis appears to have
divergent effects in cancer, with as yet apparent contrasting reports
in OC.
In the current study, we set out to evaluate whether the
CXCL16/CXCR6 pair and/or serum sCXCL16 levels were asso-
ciated with pro-metastatic or pro-inflammatory/anti-tumorigenic
properties in OC. Our results indicate that CXCL16 and CXCR6
are not predictive of survival, nor associated with T-lymphocyte
infiltration. In contrast, serum sCXCL16 proved to be an
independent prognostic factor for poor survival in OC patients,
although not associated with T-lymphocyte infiltration. In an OC
cell line and primary OC-derived malignant cells, shedding of
sCXCL16 was inhibited by ADAM10/ADAM-17 and ADAM-
10-specific inhibitor. Inhibition of ADAM activity reduced cell
migrating potential of OC cells in a scratch assay. These data
suggest that serum sCXCL16 levels may be a pseudomarker for
ADAM activity, reflecting a higher risk for metastases. Thus,
determination of serum sCXCL16 levels might help to stratify
patients into a high-risk group that may require more aggressive
treatment.
PATIENTS AND METHODS
Patient selection. Since 1985, the University Medical Center
Groningen keeps a computerised database of patients with
malignant epithelial OC treated at this hospital at any time point
during the course of their disease, prospectively collecting
information on clinicopathological characteristics and follow-up.
Tissue samples for tissue microarray construction were selected
if primary surgery was performed by a gynaecological oncologist
from the UMCG between May 1985 and June 2006 and if paraffin-
embedded tumour tissue was available. Serum is also routinely
collected and stored at  80 1C until further use. For the current
study, serum was selected from patients for whom tumour tissue
was also available. All serum samples were taken before primary
surgery.
Patients were staged according to FIGO classification (Cancer
Committee of the International Federation of Gynaecology and
Obstetrics, 1986). Tumours were graded and classified according to
WHO criteria by a gynaecological pathologist (Scully, 2004).
Adjuvant chemotherapy generally consisted of different platinum-
based treatment regimens. Response to chemotherapy was
evaluated according to World Health Organization criteria
(1979). After treatment, patients were followed-up for at least 10
years with gradually increasing intervals.
Information on clinicopathological characteristics and follow-up
of patients was obtained from a computerised database in which
information of all patients with epithelial OC treated at our
institute is prospectively recorded. For the present study, relevant
data were transferred into a separate anonymous database. In this
separate database, patient identity was protected by study-specific,
unique patient codes. In case of uncertainties with respect to
clinicopathological and follow-up data, the larger databases could
only be checked through two data managers who have daily
responsibilities for the larger database, thereby ascertaining the
protection of patients’ identity. According to Dutch law no
approval from our IRB was needed.
Tissue microarray (TMA) construction. Tissue microarrays were
constructed as previously described (Kononen et al, 1998; Rosen
et al, 2004). For 306 patients, enough tumour tissue was available
to construct a TMA. The majority of patients presented with
advanced stage, serous, high-grade tumours. After surgery, 56% of
all patients were optimally or completely debulked. Most patients
received adjuvant platinum-based chemotherapy. The median
survival for all patients was 42 months. Patient characteristics are
summarised in Supplementary Data 1.
In brief, paraffin-embedded tissue blocks containing tumour in
ovarian and omental tissue, and corresponding haematoxylin and
eosin (H&E)-stained slides were retrieved from the pathology
archives. Representative areas of tumour were marked on the
H&E-stained slides. Next, using these H&E slides for reference,
four 0.6mm core biopsies were taken from each tumour specimen
and arrayed on a recipient paraffin block using a tissue
microarrayer (Beecher instruments, Silver Spring, Maryland,
USA). Adhesion of cores to the recipient block was accomplished
by placing the blocks in a 37 1C incubator for 15min. For staining,
4 mm sections were cut from each TMA block. H&E staining was
performed to verify the presence of tumour in the arrayed samples.
Immunohistochemistry of TMA sections. In brief, TMA sections
were dewaxed in xylene and rehydrated using graded concentra-
tions of ethanol to distilled water. After antigen retrieval,
endogenous peroxidase activity was blocked by submersion of
sections in a 0.3% H2O2 solution for 30min. Sections were
incubated with anti-CXCR6 (R&D systems, Minneapolis, MN,
USA, clone 56811) and anti-CXCL16 (R&D systems, AF976) for
60min at room temperature. Sections were subsequently incubated
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with Dako Envisionþ for 30min at room temperature (Dako,
Glostrup, Denmark). The antigen–antibody reactions were visua-
lised with 3,30-diaminobenzidine. Sections were counterstained
with haematoxylin. Furthermore, previously published CD8,
CD45R0, and FoxP3 stainings were used in statistical analyses
(Leffers et al, 2009).
To obtain a high concordance rate with whole tissue slides, the
standard minimum of two cores per OC patient had to be present
to be included in analysis. As an additional criterion, a minimum
of 20% tumour tissue had to be present on the TMA for a sample
to be entered into analysis (Rosen et al, 2004). For all stainings, the
scoring system proposed by Ruiter et al (1998) was used. The
intensity of staining was scored as 0, 1, 2, or 3, indicating absent,
weak, positive, or strong positive expression, respectively. For
further analysis, the mean of the all cores available per patient
was taken as final score. In total, 273 patients (89%) were evaluable
for CXCL16 expression and 268 patients (87.6%) for CXCR6
expression.
Cells lines and primary patient-derived OC samples. Ovarian
cancer cell line A2780 (American Type Culture Collection, ATCC,
Manassas, VA, USA) was cultured in RPMI 1640 (Lonza, Basel,
Switzerland), supplemented with 10% fetal calf serum (FCS). Fresh
tissue and ascites samples were collected at primary surgery.
Tissues were minced and adherent cells were cultured in RPMI
1640 with 10% FCS. Informed consent was obtained for the
collection and storage of tumour samples. All cells were cultured at
37 1C, in a humidified 5% CO2 atmosphere.
In vitro CXCL16, ADAM-10, and ADAM-17 detection. A2780
and primary OC cells were plated (25 000 cells per well, borosilicate
chambered coverglass, Lab-Tek, Nalge Nunc International, Ros-
kilde, Denmark) and subsequently cultured in the presence or
absence of ADAM inhibitor TNF-a Protease Inhibitor-2 (TAPI-2,
Enzo Life Sciences, Farmingdale, NY, USA) or GI254023x (Tocris
Biosciences, Bristol, UK) at 100 mM for 48 h. Culture supernatants
and cell lysates were stored for ELISA’s and western blotting.
To determine CXCL16 levels by confocal microscopy, cells were
stained with anti-CXCL16 (R&D systems, AF976) and appropriate
secondary antibody (Invitrogen, Carlsbad, CA, USA, Alexa Fluor
488 Donkey Anti-Goat IgG (Hþ L)). To determine ADAM levels,
cells were first fixed with 4% PFA and then stained with anti-
ADAM-10 (Abcam, Cambridge, UK; Ab1997) or anti-ADAM-17
(Abcam, Ab57484) and Alexa Fluors 488-conjugated secondary
antibodies (Invitrogen, Goat Anti-Mouse IgG (Hþ L) and Goat
Anti-Rabbit IgG (Hþ L)). Fluorescent intensity was quantified
with ImageJ software (National Institutes of Health, Bethesda, MD,
USA) (corrected total cell fluorescence).
Western blot analysis was performed using cell lysates of non-
treated and treated cells. Proteins were separated by electrophoresis
on a 12% acrylamide gel and subsequently transferred to a
nitrocellulose membrane. After 1 h blocking with 5% ELK,
antibody staining was performed using anti-CXCL16 (R&D
systems AF976), anti-ADAM-10 (Abcam, Ab1997), and anti-
ADAM-17 (Abcam, Ab57484; see Supplementary Data 4A for
antibody testing). Appropriate secondary HRP-conjugated anti-
bodies were purchased from Dako, and protein bands were
visualised using Luminol-based enhanced chemiluminescence
(Pierce, Thermo Scientific, Waltham, MA, USA; SuperSignal West
Dura). As a control for protein loading, b-actin staining was
performed (Abcam).
Flow cytometric analysis was performed on A2780 cells, which
were treated as above described. Subsequently, cells were harvested
using cell scrapers to prevent trypsin-mediated cleavage of
CXCL16. Cells were stained with anti-CXCL16 (R&D systems
AF976) and appropriate secondary antibody (Invitrogen, Alexa
Fluor 488 Donkey Anti-Goat IgG (Hþ L)) and subsequently
analysed on a BD Accuri C6 flow cytometer (BD Biosciences,
Franklin Lakes, NJ, USA) and accessory CFlow Plus analysis
software (BD Biosciences).
ELISA kits were purchased from R&D Systems (Quantikine
human CXCL16 immunoassay, catalog number DCX160), and
used according to the manufacturer’s instructions.
For qRT-PCR, total RNA was isolated from OC cells using
Trizol (Invitrogen), and quantified by Nanodrop-1000 (Nanodrop
Technologies, Wilmington, DE, USA). cDNA synthesis was
performed according to manufacturer’s recommendations using
the iScript cDNA synthesis kit (Bio-Rad, Richmond, CA, USA).
Levels of cDNA targets were quantified with the TaqMan
gene expression assay, using iTaq Universal SYBR Green
Supermix (Bio-Rad), commercial primer/probe sets for Adam10
(Hs00153853_m1) and Adam17 (Hs01041915_m1; Invitrogen Life
Technologies, Carlsbad CA, USA) and the ABI 7900HT Sequence
Detection System (Applied Biosystems, Foster City, CA, USA). All
samples were run in duplicate (CT-value, s.d.o1) and values were
corrected for the expression of housekeeping genes (B2M:
Hs00984230_m1 and PPIA: Hs04194521_s1).
Scratch assays and cell proliferation assays. Scratch assays were
used to assess in vitro motility of OC cells. To this end, A2780 and
primary OC cells were plated (500 000 cells per six well) overnight
and subsequently cultured in serum-free medium for an additional
48 h to obtain a complete monolayer. Then a scratch was made
using a 200-ml pipette tip, and cells were incubated in the presence
or absence of TAPI-2, GI254023x, or solvent control in media
containing 10% FCS. Wound healing was visualised after 24 h of
incubation with microscopy (EVOS, digital inverted microscope,
Advanced Microscopy Group (AMG), Bothell, WA, USA), and the
distance covered by the cells was determined using ImageJ
software. Of note, for long-term inhibition activity, scratch size
was measured every day until 96 h.
To exclude inhibiting effects on cell growth or cell viability by
ADAM inhibition, A2780 cells were seeded in a 96-wells plate
(5000 cells per well) and allowed to adhere overnight. Subse-
quently, TAPI-2 and GI254023x or solvent controls were added
and incubated for an additional 48 h. Then cell growth/cell viability
was assessed using MTS assays (CellTiter 96 AQueous One
Solution Cell Proliferation, Promega, Madison, WI, USA). Of note,
a positive ‘100% death control’ was included whereby cells were
treated with 20% ethanol. OD490 of this death control was
subtracted from all conditional ODs. Cell viability was calculated as
percentage of medium control.
Statistics. Immunohistochemistry scores of CXCL16 and CXCR6
were dichotomised for statistical analysis, in which scores 0 and 1
were considered low expression, whereas scores 2 and 3 were
considered high expression. When ovarian tissue was not available
or lost during histological processing, omental tissue was used in
statistical analysis. For sCXCL16 concentrations in serum, the
median (3.35 ngml 1) was used as cutoff point, considering
o3.35 ngml 1 serum sCXCL16 as low (score 0) and
43.35 ngml 1 as high (score 1).
Associations between chemokines and clinicopathological
characteristics were tested using logistic regression. Mann–Whitney
U-tests were used to determine differences between chemokine
(receptor) expression and tumour infiltrating lymphocyte
counts. Disease-specific survival (DSS) was defined as date of
surgery until death of OC, or date of last follow-up. DSS was
estimated using the Kaplan–Meier method. Univariate and
multivariate analysis were performed using the Cox proportional
hazards model. Only variables associated with DSS in univariate
analysis were entered into multivariate analysis. Associations
in CXCL16 or sCXCL16 expression between medium and
TAPI-2/GI254023x-treated samples were assessed using Wilcoxon
signed rank tests.
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For all tests, P-valueso0.05 were considered significant (where
indicated: *Po0.05; **Po0.01; ***Po0.001). All P-values were
two-sided. Statistical analyses were performed using PASW 18.0.3
software package for Windows (IBM, Armonk, NY, USA) or Prism
software (Graphpad, La Jolla, CA, USA).
RESULTS
CXCL16 and CXCR6 are co-expressed and do not differ between
primary tumour and metastases. The expression of CXCL16 and
CXCR6 was analysed on an in-house constructed TMA comprising
material of 306 OC patients. In this TMA, CXCL16 and CXCR6
levels were scored according to low and high staining intensity (see
Figure1A for representative examples). CXCL16 expression was
low in 179 (65.6%) patients and high in 94 (34.4%) patients,
whereas CXCR6 expression was low in 131 (48.9%) patients and
high in 137 (51.1%) patients. Expression levels of CXCL16 and
CXCR6 in tumour tissue were correlated (odds ratio¼ 2.28, 95%
confidence interval (CI)¼ 1.36–3.82, P¼ 0.002), indicating that
CXCL16 and CXCR6 are often co-expressed. Of note, OC often
spreads intraperitoneally, most notably to the omentum. The TMA
contained paired ovarian and omental tumour samples for 111
patients, but no significant differences were detected between
ovarian and omental CXCL16 and CXCR6 expression (Wilcoxon
signed rank test, P¼ 0.517, Figure 1B and C). Thus, CXCL16 and
CXCR6 are often co-expressed and show no differential expression
pattern between primary tumour and metastases.
CXCL16 and CXCR6 expression do not associate with
clinicopathological factors or tumour infiltrating lymphocytes.
CXCL16 and CXCR6 expression did not associate with any of the
well-known clinicopathological factors, such as age, stage, tumour
grade, histology, and the presence of residual tumour after
debulking surgery, although high expression of CXCL16 was more
often seen in serous tumours (Table 1). Similarly, co-expression of
CXCL16/CXCR6 was not associated with these factors (data not
shown). In addition, in univariate analysis high or low CXCL16
and CXCR6 expression was not associated with survival (Figure 2A
and B, respectively, Table 2). Earlier studies in colorectal cancer
indicated that CXCL16/CXCR6 expression correlates with T-lym-
phocyte infiltration (Hojo et al, 2007). In our TMA, we previously
identified that the presence of CD8þ CTLs and especially a high
ratio between CD8þ CTLs and FoxP3þ Tregs predicts improved
prognosis (Leffers et al, 2009). However, there was no association
between CXCL16 or CXCR6 expression and tumour infiltrating
CD8þ CTL, FoxP3þ Treg, or CD45R0þ memory T lymphocytes
(Supplementary Data 2). Furthermore, the ratio between CD8þ
CTLs and FoxP3þ Tregs did not differ between high and low
CXCL16 or CXCR6 expression (Supplementary Data 3A and 3B),
nor were differences detected between CXCL16:CXCR6 high/low
groups (Supplementary Data 3C). This suggests that in this OC
cohort, the CXCL16/CXCR6 chemokine/receptor pair does not
directly modulate anti-tumour immune responses.
High serum sCXCL16 levels independently predicts poor
survival in OC. The cleavage of the extracellular domain of
CXCL16 into sCXCL16 has been previously reported for various
types of cancer (Gough et al, 2004; Schramme et al, 2008).
Therefore, serum levels of sCXCL16 were determined for 118 OC
patients, of which pre-treatment serum samples were available.
The concentration of sCXCL16 ranged from 0.02 to 6.66 ngml 1,
with a median of 3.35 ngml 1. Notably, although sCXCL16 is
generated by cleavage of CXCL16 from the cell membrane, no
association between CXCL16 staining intensity and sCXCL16
concentration was detected (data not shown). In the evaluable OC
patients, high pre-treatment levels of serum sCXCL16 associated
with older age, high grade tumours, and 42 cm residual tumour
after primary debulking (Table 1). More importantly, serum levels
of sCXCL16 correlated with survival in OC patients, with high
serum sCXCL16 being predictive of poor survival in univariate
analysis (Figure 2C, Table 2). Specifically, patients with high
sCXCL16 had a mean survival time of 58 months (95% CI¼
40.0–77.8), whereas patients with low serum sCXCL16 had an
approximate three-fold increase in mean survival of 156 months
(95% CI¼ 123.5–188.6). A subsequent multivariate analysis with
established prognostic factors as covariates revealed that high
serum sCXCL16 levels retained its prognostic value, independent
of age, stage, grade, histology, and residual tumour after debulking



























Figure 1. CXCL16 and CXCR6 expression do not differ between primary tumour and metastases. (A) Representative examples of CXCL16 and
CXCR6 staining. (I) CXCL16 weak, (II) CXCL16 strong, (III) CXCR6 weak, (IV) CXCR6 strong. (B) CXCL16 score between primary OC and omental
tissue. (C) CXCR6 score between primary OC and omental tissue.
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performed in patients with high-stage disease (i.e., stage IIIb and IV),
sCXCL16 retained its prognostic effect in both univariate (hazard
ratio (HR)¼ 2.09, 95% CI¼ 1.25–3.49, P¼ 0.005) and multivariate
analysis (HR¼ 2.24, 95% CI¼ 1.25–4.03, P¼ 0.007; data not
shown). Therefore, the prognostic effect of sCXCL16 is independent
and not due to an association with OC stage. Thus, sCXCL16 is an
independent predictor of poor survival in OC patients.
In previous studies in colorectal cancer, serum sCXCL16 levels
were found to associate with immune infiltration. However, in our
cohort, the level of serum sCXCL16 did not correlate with the
number of tumour infiltrating CD8þ CTL, FoxP3þ Treg, or
CD45R0þ memory T lymphocytes (Supplementary Data 2), nor
with the ratio between CD8þ CTLs and FoxP3þ Tregs
(Supplementary Data 3D). Thus, the predictive value of serum
sCXCL16 is not related to adaptive immune responses as identified
in colorectal cancer.
CXCL16 shedding is inhibited by ADAM protease inhibitors.
Serum CXCL16 did not associate with immune parameters in the
tumours nor correlated with CXCL16/CXCR6 expression. This
suggested that sCXCL16 was probably not associated with
CXCL16/CXCR6 signalling itself, but may indirectly reflect other
tumorigenic processes. In this respect, it has been described that
CXCL16 can be cleaved by ADAM-10 and ADAM-17 thereby
generating sCXCL16 (Gough et al, 2004; Schramme et al, 2008). In
addition, ADAM protease activity is well known to be associated
with increased metastatic behaviour. Hence, CXCL16 processing
into sCXCL16 might be a pseudomarker for ADAM activity. To
evaluate this possibility in vitro, A2780 OC cells were selected as
model cell line, as these cells expressed CXCL16, ADAM-10, and
ADAM-17 (Figure 3A, Supplementary Data 4A). Subsequently,
A2780 cells were incubated with the ADAM-10/ADAM-17
inhibitor TAPI-2, as well as the ADAM-10-selective inhibitor
GI254023x, as the level of expressed ADAM-10 was on average
9.8-fold higher on mRNA level compared with ADAM-17
(Supplementary Data 4C). In line with this, ADAM10 protein
levels were abundant, whereas ADAM17 levels were minimally
detectable (Figure 3A, see Supplementary Data 4B for complete
blots). Incubation with the ADAM-10/ADAM-17 inhibitor TAPI-2,
clearly upregulated the level of membrane-expressed CXCL16 as
shown by immunofluorescent imaging, flow cytometry, and
western blot analysis (Figure 3B and C, see Supplementary Data
4D for complete blots). In addition, GI254023x also prevented
CXCL16 shedding from the cell membrane and was even more
potent than TAPI-2 (Figure 3B and C). Similar to A2780, most OC
cells from a small panel of primary patient-derived samples mainly
expressed ADAM-10 over ADAM-17 (Figure 3D, Supplementary
Data 4C). In line with this, treatment with both TAPI-2 and
GI254023x highly increased CXCL16 levels on the cell surface of
primary OC cells (Figure 3E and F). Correspondingly, the
supernatant of A2780 and primary OC cell cultures contained
high (ngml 1) levels of sCXCL16 in standard culture conditions
that was reduced upon TAPI-2 (43.9% inhibition) or GI254023x
(89.7% inhibition) treatment (Figure 3G–I). Thus, sCXCL16
shedding from the membrane of OC cells is likely ADAM
dependent, whereby ADAM-10 seems to be most important.
ADAM proteases regulate cell migrating potential of OC
cells. To evaluate the functional consequences of ADAM
activity, cell migration was assessed using scratch assays. In
non-treated A2780 cells, the total scratch size was reduced by
B50% within 24 h (Figure 4A), equaling an average distance
covered of 105 mm (Figure 4B). In contrast, migration of TAPI-2
as well as GI254023x-treated A2780 cells was strongly inhibited
(Figure 4A), covering, respectively, 60 and 50 mm of the scratch
within 24 h (Figure 4B). In line with this, TAPI-2 and GI254023x
reduced cell migration of primary patient-derived OC cells
(Figure 4C and D). Of note, migration of primary OC showed a
less structured migration pattern compared with the A2780
cell line (Figure 4A and C). The effect on cell migration by
ADAM inhibition lasted up to at least 4 days (Figure 4E), and
Table 1. Logistic regressions of CXCL16/CXCR6 expression levels and clinicopathological characteristics
High CXCR6 expression High CXCL16 High sCXCL16
Age X58 years 1.43 (0.89–2.32) 0.142 0.99 (0.60–1.63) 0.958 3.28 (1.54–6.97) 0.002**
High-stage tumours 0.90 (0.52–1.56) 0.704 0.93 (0.52–1.66) 0.817 2.12 (0.98–4.58) 0.056
High-grade tumours 0.76 (0.44–1.32) 0.760 1.05 (0.58–1.89) 0.869 2.63 (1.22–5.67) 0.014*
Serous tumours 0.80 (0.46–1.40) 0.437 1.94 (1.05–3.56) 0.034* 2.11 (0.97–4.61) 0.060
42 cm Residual tumour 0.86 (0.49–1.51) 0.604 1.26 (0.70–2.27) 0.434 2.45 (1.137–5.31) 0.023*
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Figure 2. Serum sCXCL16 levels predict poor survival in ovarian
cancer patients. Kaplan–Meier survival curve for (A) CXCL16,
(B) CXCR6, and (C) serum sCXCL16.
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was not caused by the used solvents or a reduction in cell
proliferation/cell viability (Figure 4B, D and F). These results
suggest that active ADAMs positively regulate the migrating
potential of OC cells.
DISCUSSION
The role of CXCL16 and CXCR6 in cancer is ambiguous and
probably cancer type specific, as their expression has been
associated with pro-metastatic as well as anti-tumorigenic functions.
The current study, performed in a large cohort of 306 OC
patients, indicated that neither expression of membrane CXCL16
nor expression of membrane CXCR6 is associated with survival.
In contrast, pre-treatment serum levels of sCXCL16 independently
predicted survival, showing reduced survival time in patients with
high serum sCXCL16 levels. Of note, serum sCXCL16 levels did
not correlate with tumour infiltration of immune cells. Further-
more, in vitro experiments showed that the inhibition of ADAM-
10/17 prevented cleavage of CXCL16 from the membrane of
(primary) OC cells, which is according to literature. In addition,
ADAM inhibition in (primary) OC cells strongly reduced tumour
cell migration. Therefore, elevated serum levels of sCXCL16 may
be a pseudomarker for high ADAM activity and thereby predict a
subset of patients with a more aggressive tumour.
In this cohort of OC patients, high serum sCXCL16 levels were
predictive for poor survival. In addition to sCXCL16, tumour stage
also associated with survival time. However, when survival analysis
was performed in patients with high-stage disease (i.e., stage IIIb
and IV), sCXCL16 retained its prognostic effect in both univariate
and multivariate analysis. Therefore, the prognostic effect of
sCXCL16 is independent and not due to an association with OC
stage. This association of high serum sCXCL16 levels with poor
survival in OC patients is in agreement with a previous study in
colorectal cancer patients whereby high sCXCL16 serum levels also
negatively correlated with survival (Matsushita et al, 2012). In
addition, serum levels of sCXCL16 were elevated in prostate (Sung
et al, 2008) and pancreatic (Wente et al, 2008) cancer patients
compared with healthy controls. In contrast, no correlation was
found between membrane CXCL16 levels and survival, although
there was a modest association between CXCL16 and serous
histology, an OC subtype with an unfavourable prognosis. This
contrasts with a previous study in 56 OC patients in which
CXCL16 associated with decreased survival (Guo et al, 2011).
However, no multivariate analysis was performed and compared
with our study, median follow-up was shorter. In addition, the
included patients presented with more favourable clinicopatho-
logical characteristics, with a considerably better 5-year survival
(70% vs 39%), which might influence outcome. On the other hand,
CXCL16 expression was associated with improved prognosis in
renal cell (Gutwein et al, 2009) and colorectal cancer (Hojo et al,
2007). This suggests that the effect of CXCL16 and CXCR6 on
clinical outcome differs between tumour type and study design.
Previously, CXCL16 and CXCR6 were reported to be differen-
tially expressed between primary tumor and metastases, with, for
example, elevated CXCL16 and CXCR6 mRNA levels in bone and
liver metastases compared with corresponding primary tumours in
prostate cancer (Lu et al, 2008). Similarly, immunohistochemical
analysis of breast cancer (Lin et al, 2009), nasopharyngeal
carcinomas (Ou et al, 2006), and melanomas (Seidl et al, 2007)
revealed CXCR6 expression in metastatic carcinoma, whereas
primary tumours largely lacked CXCR6. In prostate cancer and
renal and hepatocellular carcinoma, CXCL16 induced migration of
CXCR6-expressing cell lines (Lu et al, 2008; Wang et al, 2008; Lin
et al, 2009; Gao et al, 2012; Oldham et al, 2012). Moreover, it was
demonstrated that CXCL16 treatment induced proliferation,
migration, and invasive growth in CXCR6-expressing colorectal
cancer cell lines (Matsushita et al, 2012). In this way, CXCL16/
CXCR6 signalling contributes to detachment of tumour cells and
promotes subsequent migration. In line with this, constitutive
expression of CXCL16 and/or CXCR6 was found in many cancer
cell lines, among which prostate (Hu et al, 2008; Lu et al, 2008; Ha
et al, 2011), breast (Lin et al, 2009), nasopharyngeal (Ou et al,
2006), and pancreatic cancer (Wente et al, 2008). However, in our
cohort, CXCL16 and CXCR6 expression levels did not differ
between primary ovarian tumour tissue and omental metastases.
The lack of such an association in OC could be due to the route
of metastasis in OC. All other tumour types predominantly
metastasise haematogenous or via lymph nodes. In contrast,
omental metastases in OC arise from an exfoliative spread from the
surface of the ovaries into the abdominal cavity. The detachment of
tumour cells per se may thus be more important than the homing
of tumour cells to a specific location, as is necessary in case of
haematogenous metastasis.
In studies where high tumoural CXCL16 expression was
associated with prolonged survival, the survival benefits were
attributed to the T-lymphocyte attracting properties of CXCL16
(Hojo et al, 2007). However, we did not find an association
between tumour infiltrating lymphocytes and sCXL16, CXCL16, or
CXCR6. Therefore, high serum sCXCL16 levels are probably not
associated with CXCL16/CXCR6 signalling itself, but may
indirectly reflect other tumorigenic processes. In this respect,
previous studies identified ADAM-10 and ADAM-17 to be
responsible for CXCL16 cleavage (Gough et al, 2004; Schramme
et al, 2008; Gutwein et al, 2009). Thus, serum levels of sCXCL16
Table 2. Cox regression survival analysis of CXCL16/CXCR6/sCXCL16 expression levels.
Univariate analysis Multivariate analysis
High sCXCL16 2.34 (1.44–3.81) 0.001** 2.47 (1.38–4.39) 0.002**
High CXCL16 1.13 (0.82–1.55) 0.461 NA
High CXCR6 expression 1.18 (0.86–1.60) 0.308 NA
Age X58 years 1.81 (1.34–2.44) o0.001*** 1.31 (0.70–2.47) 0.399
High-stage tumours 9.77 (5.64–16.93) o0.001*** 7.44 (2.27–24.42) 0.001**
High-grade tumours 3.40 (2.43–4.76) o0.001*** 1.66 (0.89–3.11) 0.115
Serous tumours 3.56 (2.43–5.22) o0.001*** 1.86 (0.88–3.92) 0.104
42 cm Residual tumour 4.97 (3.59–6.88) o0.001*** 1.41 (0.73–2.70) 0.307
Abbreviation: NA, not applicable. All values are represented as: odds ratio (95% confidence interval), P-value. **Po0.01; ***Po0.001
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might reflect tumour-associated ADAM activity. A similar
association has previously been reported for ALCAM, an adhesion
molecule also cleaved by ADAMs, with high serum sALCAM being
predictive of poor survival (Carbotti et al, 2013). Indeed, in vitro
inhibition of ADAM-10 and ADAM-17 enhanced CXCL16
expression on the membrane of (primary) OC cells and reduced
sCXCL16 levels in culture supernatants. In addition, ADAM
inhibition reduced cell migration of (primary) OC cells in a scratch
assay. Of note, in all in vitro assays, the specific ADAM-10
inhibitor seemed to be more potent than the ADAM-10/ADAM-17
inhibitor. This is probably due to the expression levels of ADAMs,
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Figure 3. ADAM proteases regulate CXCL16 shedding. (A) Representative picture of CXCL16, ADAM-10, and ADAM-17 staining on the OC cell
line A2780 as determined by fluorescent imaging (performed on PFA fixed cells) and western blot analysis. Conjugate controls were included to
determine background fluorescence. (B) Levels of CXCL16 were determined on the OC cell line A2780 with or without TAPI-2/GI254023x (100mM)
treatment, using confocal microscopy, flow cytometry, and western blot analysis. Of note, MFI of conjugate control used in flow cytometric analysis
was 21 000. (C) Analysed CXCL16 levels (corrected total cell fluorescence (CTCF)) on A2780 cells (n¼ 4) with or without TAPI-2/ GI254023x
(100mM) treatment. Conjugate control (Alexafluor-488 Donkey anti-Goat) was used to determine background fluorescence. (D) Analysed ADAM-10
and ADAM-17 expression levels (CTCF) and background fluorescence with conjugate control on a small panel or primary derived OC cells (n¼ 6).
Depicted confocal images are a representative of ADAM-10 and ADAM-17 staining in primary OC. (E) Analysed CXCL16 levels (CTCF) on primary
OC (n¼11) with or without TAPI-2 treatment (100mM). Depicted confocal images are a representative of CXCL16 fluorescent staining on medium
and TAPI-2-treated primary OC cells. (F) Analysed CXCL16 levels (CTCF) on primary OC (n¼ 7) with or without GI254023x treatment (100mM).
Depicted confocal images are a representative of CXCL16 staining on medium and GI254023x-treated primary OC cells. (G) sCXCL16 levels in
supernatants of untreated vs TAPI-2/ GI254023x-treated (100mM) A2780 cells. (H) sCXCL16 levels in supernatants of untreated vs TAPI-2 (100mM)-
treated primary OC cells (n¼10). TAPI-2 inhibits 43.9% of all sCXCL16 release on average. (I) sCXCL16 levels in supernatants of untreated vs
GI254023x (100mM)-treated primary OC cells (n¼6). GI254023x inhibits 89.7% of all sCXCL16 release on average.
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A2780 t=48 h
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Figure 4. ADAM proteases regulate migratory behaviour of ovarian cancer (OC) cells. (A) Representative picture of the scratch assay at
t¼0 vs t¼ 24h in medium or TAPI-2/ GI254023x (100mM)-treated A2780 cells. (B) Analysed distance covered by medium or TAPI-2/GI254023x
(100mM)-treated A2780 cells or with solvent control (DMSO) within 24 h. (C) Representative picture of the scratch assay at t¼ 0 vs t¼24 h in
medium or TAPI-2/ GI254023x (100mM)-treated primary OC cells. (D) Analysed distance covered by medium or TAPI-2/GI254023x (100mM)- or
solvent control (DMSO)-treated primary OC cells within 24 h. (E) Long-term follow-up (4 days) of scratch size in medium or TAPI-2/GI254023x
(100mM)-treated A2780 cells. (F) Effect of TAPI-2/GI254023x (100mM) or solvent control (DMSO) on A2780 cell proliferation/cell viability as
determined by MTS assays after 48 h of incubation.
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ADAM-10 over ADAM-17. In addition, previous studies also
showed that CXCL16 shedding was mainly caused by ADAM-10
and not by ADAM-17 (Gough et al, 2004; Gutwein et al, 2009). In
line with this, selective ADAM-10 inhibition almost completely
inhibited the release of sCXCL16, whereby 89.7% of CXCL16
shedding was blocked. Taken together, CXCL16 shedding from OC
cells is likely regulated by ADAMs, especially ADAM-10, and
inhibition of their activity inhibits the cell migrating potential of
OC cells.
Based on these findings, high sCXCL16 levels in serum of OC
patients may reflect higher ADAM activity and a more aggressive
OC subtype. Indeed, expression of ADAM metalloproteinases
promotes cancer cell growth, metastatic behaviour, and tumour
progression (Mochizuki and Okada, 2007; Rocks et al, 2008). Of
note, it has been shown that direct in vivo quantification of ADAM
activity is complicated. Specifically, mRNA expression of ADAM-
17 in OC was not representative of protein expression because of
posttranslational modifications (Sinnathamby et al, 2011). Further-
more, measurement of ADAM activity is hampered by endogenous
inhibitors, such as tissue inhibitor of metalloproteinases. Therefore,
sCXCL16 may be a useful pseudomarker to predict an aggressive
tumour type with higher ADAM activity in OC.
In conclusion, high pre-treatment serum sCXCL16 is a prognostic
marker for poor survival in OC patients, possibly reflecting higher
ADAM activity. Therefore, serum sCXCL16 levels may be a pseu-
domarker that identifies patients with more aggressive tumours.
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